BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image
Active
Mainboard

Rubicon Research Ltd

Rubicon Research Ltd IPO Details

Listing Date

16 Oct 2025

Bid Price

₹461 - ₹485

Lot Size

30 Shares

Minimum Investment

₹14,550 / Lot

Issue Size

₹1377.5 Crores

Employee Discount

₹46 per share

Schedule

    Here are the important dates you need to know in order to participate in this IPO

tick

Bidding starts

9th Oct

tick

Bidding ends

13th Oct

tick

Allotment of shares

14th Oct

tick

Initiation of refund

15th Oct

tick

Credit of shares to Demat account

15th Oct

tick

Listing date

16th Oct

About Rubicon Research Ltd IPO

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company focused on the development, manufacturing, and commercialisation of differentiated formulations. As of June 30, 2025, the company holds approvals for 72 products under the US FDA’s ANDA and NDA framework, with 66 products currently commercialised. Its presence in the US generic pharmaceutical market, valued at USD 2,455.7 million, generated revenue of USD 195 million for Rubicon in Fiscal 2024. The company has an additional 17 products awaiting US FDA approval and 63 products in various stages of development, reflecting a consistent pipeline for future growth.
 

Rubicon Research also markets over 350 SKUs to 96 customers, including major wholesalers covering more than 90% of wholesale drug distribution in the US. The company extends its operations internationally with 48 product applications across Australia, the UK, Singapore, Saudi Arabia, and the UAE. Its services include contract manufacturing for select customers in India, Australia, and New Zealand. Rubicon operates three manufacturing facilities in India and maintains two US FDA inspected R&D centres in India and Canada, supporting both domestic and international product development.

Shareholder Pattern

  Pre-Issue Post-Issue
Promoter Group 77.34% 61.79%
Public Group 22.66% 38.21%

Rubicon Research Ltd IPO Reservation

QIB Shares Offered 85,09,788 (29.96%)
NII (HNI) Shares Offered 42,54,894 (14.98%)
Retail Shares Offered 28,36,596 (9.99%)
Anchor Investor Shares Offered 1,27,64,681 (44.94%)
Total Shares Offered 2,84,02,040
Total Shares With Anchor Investor 2,84,02,040

Rubicon Research Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 30 ₹14,550
Retail (Max) 13 390 ₹1,89,150
S HNI (Min) 14 420 ₹2,03,700
S HNI (Max) 68 2,040 ₹9,89,400
B HNI (MIN) 69 2,070 ₹10,03,950

Rubicon Research Ltd IPO Anchor Investor Details

Bid Date October 08, 2025

Rubicon Research Ltd IPO registrar

MUFG Intime India Pvt Ltd
Phone Number +91 81081 14949
Email Id rubicon.ipo @linkintime.co.in
Website www.linkintime.co.in / https://in.mpms.mufg.com

Rubicon Research Ltd IPO Lead Manager

1. Axis Capital Ltd

2. IIFL Securities Ltd

3. JM Financial Ltd

4. SBI Capital Markets Ltd

Rubicon Research Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹540.98 cr ₹385 cr ₹286.38 cr
Reserves and Surplus ₹525.57 cr ₹369.79 cr ₹281.3 cr
Total Borrowing ₹393.17 cr ₹396.41 cr ₹317.91 cr

Rubicon Research Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid No. of subscribed
Qualified Institutional Buyers (QIBs) 89,52,820 1,16,61,67,740 130.26
Non Institutional Investors (NIIs) 44,76,409 43,69,39,170 97.61
NII(Bid amount of more than Ten Lakh Rupees) 29,84,273 33,40,22,190 111.93
NII(Bid amount of more than 2 Lakh < 10 Rupees) 14,92,136 10,29,16,980 68.97
Retail Individual Investors (RIIs) 29,84,273 10,58,65,470 35.47
Total 1,64,55,670 1,70,96,80,620 103.9

Strength of Rubicon Research Ltd

  • We are the fastest growing Indian pharmaceutical company amongst our peers and the only Indian company focused completely on the US market.
  • Our data-driven product selection framework has allowed us to build a product portfolio with a combination of new and specialty products allowing us to withstand pricing pressures.
  • Our R&D capabilities and continuing investment allow us to pursue complex products that offer strong revenue opportunities.
  • Robust sales and distribution capabilities in the US.
  • Strong track record of compliance combined with expertise in cost effective manufacturing
  • Experienced and entrepreneurial management team with a proven track record and marquee private equity investor.

Risks Involved

  • We derive Rs.3,507.36 million and 99.50%, and Rs.12,649.23 million and 98.49%, respectively, of our revenue from operations from the United States for the three month period ended June 30, 2025 and Fiscal 2025, respectively, and any adverse developments in the United States such as imposition of tariffs could have an adverse effect on our business and results of operations.
  • As the manufacture of our products is technically complex and highly regulated, product recalls, regulatory inspection failures or shortcomings at our manufacturing facilities or other problems may reduce sales, adversely affect our business, financial condition and results of operations and delay the launch of new products, and in some cases may lead to closures of our facilities.
  • We have a history of net losses, negative earnings per share ("EPS") and return on capital employed. We need to generate and sustain increased revenues while managing our expenses to achieve profitability, and our inability to achieve these goals may have an adverse effect on our business, results of operations, cash flows and financial condition.
  • In Fiscals 2025, 2024 and 2023, and the three month period ended June 30, 2025 and 2024 we derived 71.22%, 65.14% and 62.99%, and 77.04% and 70.46%, respectively, of our revenue from sale of goods from our top five customers and the loss of one or more such customers could adversely affect our business and prospects.
  • Our operations are subject to high working capital and capital expenditure requirements, and our inability to maintain an optimal level of working capital or financing required may impact our operations adversely.
  • Any disruption, breakdown or shutdown of our research and development and manufacturing facilities may have a material adverse effect on our business, financial condition, results of operations and cash flows.
  • Our Company is involved in certain legal proceedings. Any adverse decision in such proceedings may render us/them liable to liabilities/penalties and may adversely affect our business, financial condition, results of operations and cash flows.
  • Our success depends on our ability to execute our growth strategies. If we are unable to sustain or manage our growth, our business, results of operations, cash flows and financial condition may be adversely affected.
  • We face significant competitive pressures in our business from other pharmaceutical manufacturers. Our inability to compete effectively would be detrimental to our business and prospects for future growth.
  • The market in which we operate is subject to consolidation and disruption, and our inability to navigate such changes could adversely affect our business, financial condition and results of operation.
stock

Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Industry Outlook of Rubicon Research IPO

  • Indian pharmaceutical formulations sector appears to be growing steadily, especially in regulated markets such as the United States and Europe.

  • Demand in the US generics and specialty products market is under pressure from regulatory complexity, cost of raw materials, and competition from other Asian players.

  • R&D investment is increasing among pharma firms, with more companies seeking ANDA and NDA approvals, drug-device combinations and complex dosage forms.

  • Regulatory requirements (US FDA, WHO-GMP, Health Canada etc.) are shaping manufacturing and compliance costs. Firms with accredited facilities may have smoother paths to market.

  • Global health-crises, supply chain disruptions, and raw material sourcing from China are creating both risks and opportunities for Indian exporters.

  • Domestic growth (India) and demand from Europe may help offset slowing growth in the US market.

  • Firms that maintain a deep product pipeline, ensure high commercialization rates of approved products, and expand manufacturing capacity may have more consistent revenue upside.

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Rubicon Research IPO.  

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
KSH International Limited IPO
Bidding Period
16th Dec 2025 - 12th Dec 2025
Price Range
₹365.0 - 384.0
IPO Size
₹7,10,00,00,000
Global Ocean Logistics India Limited IPO
Bidding Period
17th Dec 2025 - 12th Dec 2025
Price Range
₹74.0 - 78.0
IPO Size
₹30,41,00,000
Marc Technocrats Limited IPO
Bidding Period
17th Dec 2025 - 12th Dec 2025
Price Range
₹88.0 - 93.0
IPO Size
₹42,59,00,000
Shyam Dhani Industries Limited IPO
Bidding Period
22nd Dec 2025 - 12th Dec 2025
Price Range
₹65.0 - 70.0
IPO Size
₹38,49,00,000
Aarvee Engineering Consultants Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AceVector Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advit Jewels Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aggcon Equipments International Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alcobrew Distilleries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allied Engineering Works Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alpine Texworld Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Amagi Media Labs Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Amir Chand Jagadish Kumar Exports Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Annu Projects Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
NEPHROCARE HEALTH SERVICES LIMITED IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹438.0 - 460.0
IPO Size
₹8,71,05,00,000
PARK MEDI WORLD LIMITED IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹154.0 - 162.0
IPO Size
₹9,20,00,00,000
SHIPWAVES ONLINE LIMITED IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹12.0 - 12.0
IPO Size
₹56,35,00,000
UNISEM AGRITECH LIMITED IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹63.0 - 65.0
IPO Size
₹21,45,00,000
WAKEFIT INNOVATIONS LIMITED IPO
Bidding Period
8th Dec 2025 - 12th Dec 2025
Price Range
₹185.0 - 195.0
IPO Size
₹12,88,89,00,000
RIDDHI DISPLAY EQUIPMENTS LIMITED IPO
Bidding Period
8th Dec 2025 - 12th Dec 2025
Price Range
₹95.0 - 100.0
IPO Size
₹24,68,00,000
PRODOCS SOLUTIONS LIMITED IPO
Bidding Period
8th Dec 2025 - 12th Dec 2025
Price Range
₹131.0 - 138.0
IPO Size
₹27,60,00,000
K V TOYS INDIA LIMITED IPO
Bidding Period
8th Dec 2025 - 12th Dec 2025
Price Range
₹227.0 - 239.0
IPO Size
₹40,15,00,000
CORONA REMEDIES LIMITED IPO
Bidding Period
8th Dec 2025 - 12th Dec 2025
Price Range
₹1008.0 - 1062.0
IPO Size
₹6,55,37,00,000
ENCOMPASS DESIGN INDIA LIMITED IPO
Bidding Period
5th Dec 2025 - 12th Dec 2025
Price Range
₹101.0 - 107.0
IPO Size
₹40,21,00,000
FLYWINGS SIMULATOR TRAINING CENTRE LIMITED IPO
Bidding Period
5th Dec 2025 - 12th Dec 2025
Price Range
₹181.0 - 191.0
IPO Size
₹57,05,00,000
METHODHUB SOFTWARE LIMITED IPO
Bidding Period
5th Dec 2025 - 12th Dec 2025
Price Range
₹190.0 - 194.0
IPO Size
₹1,03,02,00,000
LUXURY TIME LIMITED IPO
Bidding Period
4th Dec 2025 - 12th Dec 2025
Price Range
₹78.0 - 82.0
IPO Size
₹18,74,00,000
WESTERN OVERSEAS STUDY ABROAD LIMITED IPO
Bidding Period
4th Dec 2025 - 12th Dec 2025
Price Range
₹56.0 - 56.0
IPO Size
₹10,07,00,000
VIDYA WIRES LIMITED IPO
Bidding Period
3rd Dec 2025 - 12th Dec 2025
Price Range
₹48.0 - 52.0
IPO Size
₹3,00,01,00,000
MEESHO LIMITED IPO
Bidding Period
3rd Dec 2025 - 12th Dec 2025
Price Range
₹105.0 - 111.0
IPO Size
₹54,21,20,00,000
SHRI KANHA STAINLESS LIMITED IPO
Bidding Period
3rd Dec 2025 - 12th Dec 2025
Price Range
₹90.0 - 90.0
IPO Size
₹46,28,00,000
AEQUS LIMITED IPO
Bidding Period
3rd Dec 2025 - 12th Dec 2025
Price Range
₹118.0 - 124.0
IPO Size
₹9,21,81,00,000
HELLOJI HOLIDAYS LIMITED IPO
Bidding Period
2nd Dec 2025 - 12th Dec 2025
Price Range
₹110.0 - 118.0
IPO Size
₹10,96,00,000
NEOCHEM BIO SOLUTIONS LIMITED IPO
Bidding Period
2nd Dec 2025 - 12th Dec 2025
Price Range
₹93.0 - 98.0
IPO Size
₹44,97,00,000
  • All
  • MainBoard
  • SME
ENCOMPASS DESIGN INDIA LIMITED IPO
Issue Prize
107.00
Listing Day Close
193.15(80.37%)
FLYWINGS SIMULATOR TRAINING CENTRE LIMITED IPO
Issue Prize
191.00
Listing Day Close
204.75(7.33%)
METHODHUB SOFTWARE LIMITED IPO
Issue Prize
194.00
Listing Day Close
162.90(-15.98%)
LUXURY TIME LIMITED IPO
Issue Prize
82.00
Listing Day Close
163.59(100.00%)
WESTERN OVERSEAS STUDY ABROAD LIMITED IPO
Issue Prize
56.00
Listing Day Close
52.16(-7.14%)
VIDYA WIRES LIMITED IPO
Issue Prize
52.00
Listing Day Close
53.14(1.92%)
MEESHO LIMITED IPO
Issue Prize
111.00
Listing Day Close
170.20(53.15%)
SHRI KANHA STAINLESS LIMITED IPO
Issue Prize
90.00
Listing Day Close
83.60(-6.67%)
AEQUS LIMITED IPO
Issue Prize
124.00
Listing Day Close
151.50(22.58%)
HELLOJI HOLIDAYS LIMITED IPO
Issue Prize
118.00
Listing Day Close
123.90(5.08%)
NEOCHEM BIO SOLUTIONS LIMITED IPO
Issue Prize
98.00
Listing Day Close
111.80(14.29%)
INVICTA DIAGNOSTIC LIMITED IPO
Issue Prize
85.00
Listing Day Close
96.70(14.12%)
RAVELCARE LIMITED IPO
Issue Prize
130.00
Listing Day Close
190.95(46.92%)
ASTRON MULTIGRAIN LIMITED IPO
Issue Prize
63.00
Listing Day Close
47.88(-23.81%)
CLEAR SECURED SERVICES LIMITED IPO
Issue Prize
132.00
Listing Day Close
113.05(-14.39%)
SPEB ADHESIVES LIMITED IPO
Issue Prize
56.00
Listing Day Close
57.00(1.79%)
EXATO TECHNOLOGIES LIMITED IPO
Issue Prize
140.00
Listing Day Close
279.30(99.29%)
PURPLE WAVE INFOCOM LIMITED IPO
Issue Prize
126.00
Listing Day Close
130.50(3.97%)
LOGICIEL SOLUTIONS LIMITED IPO
Issue Prize
193.00
Listing Day Close
146.70(-23.83%)
MOTHER NUTRI FOODS LIMITED IPO
Issue Prize
117.00
Listing Day Close
124.30(5.98%)

Frequently Asked Questions

What is Rubicon Research Ltd IPO?

Answer Field

Rubicon Research Ltd IPO is a Mainboard IPO of 2,84,02,040 equity shares of a face value of ₹1 aggregating up to ₹1377.5 Crores. The issue is priced at ₹461 to ₹485 per share. The minimum order quantity is 30 Shares. The IPO opens on October 09, 2025, and closes on October 13, 2025. MUFG Intime India Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Rubicon Research Ltd IPO will open?

Answer Field

The Rubicon Research Ltd IPO opens on October 09, 2025 and closes on October 13, 2025.

What is the lot size of Rubicon Research Ltd?

Answer Field

Rubicon Research Ltd lot size is 30 shares, and the minimum amount required is ₹14,550.

How to apply for Rubicon Research Ltd IPO?

Answer Field

You can apply in Rubicon Research Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Rubicon Research Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Rubicon Research Ltd IPO will be done on October 14, 2025, and the allotted shares will be credited to your demat account by October 15, 2025.

When is Rubicon Research Ltd IPO listing date?

Answer Field

The Rubicon Research Ltd listing date is October 16, 2025.

Who is the registrar of Rubicon Research Ltd IPO?

Answer Field

The registrar of Rubicon Research Ltd IPO is MUFG Intime India Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

Axis Capital Ltd,IIFL Securities Ltd,JM Financial Ltd,SBI Capital Markets Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Rubicon Research Ltd IPO?

Answer Field

The fresh issue size is ₹500 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Rubicon Research Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 30 shares and ₹14,550 amount.

How can I approve the UPI mandate request for Rubicon Research Ltd IPO?

Answer Field

To apply for Rubicon Research Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Rubicon Research Ltd?

Answer Field

The price of each Rubicon Research Ltd share will be ranging in between ₹461 to ₹485 per share.

What is the cut-off time for the UPI mandate for Rubicon Research Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, October 13, 2025.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|